Minomic to Begin First-In-Human Trial of Novel Prostate Cancer Imaging ...
Australian immuno-oncology company Minomic International Ltd has struck an agreement to launch the first human study of its novel monoclonal antibody technology as an imaging agent to detect prostate, pancreatic and bladder cancers.